Paula Ragan - X4 Pharmaceuticals President CEO, Secretary, Director
| XFOR Stock | USD 0.43 0.01 1.82% |
CEO
Dr. Paula Ragan, Ph.D. is President, Chief Executive Officer, Secretary, Director of the Company. She was X4s President and Chief Executive Officer and a member of the X4 board of directors since July 2014. She has more than 18 years of experience building companies in the biotechnology industry. From August 2012 to September 2014, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc., a private biopharmaceutical company, where she led the companys business development activities. Prior to that, from January 2007 to August 2012, Dr. Ragan held leadership roles in corporate development and operations at Genzyme Corporation, a Sanofi company, where she led strategic partnering efforts for Genzymes Rare Disease business and headed the supply chain planning for Genzymes flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation since 2019.
| Age | 55 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 61 North Beacon Street, Boston, MA, United States, 02134 |
| Phone | 857 529 8300 |
| Web | https://www.x4pharma.com |
Latest Insider Transactions
Ragan received her B.S. from Tufts University and her Ph.D. from Massachusetts Institute of Technology and completed postdoctoral studies at Harvard Medical School. The Company believes that Dr. Ragan’s perspective and experience as X4’s President and Chief Executive Officer, which provides the board with historic knowledge, operational expertise and continuity, provides her with the qualifications and skills to serve on the Company’s board of directors.Paula Ragan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paula Ragan against X4 Pharmaceuticals stock is an integral part of due diligence when investing in X4 Pharmaceuticals. Paula Ragan insider activity provides valuable insight into whether X4 Pharmaceuticals is net buyers or sellers over its current business cycle. Note, X4 Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell X4 Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paula Ragan over three weeks ago Acquisition by Paula Ragan of 169940 shares of X4 Pharmaceuticals subject to Rule 16b-3 | ||
Paula Ragan over three months ago Disposition of 31897 shares by Paula Ragan of X4 Pharmaceuticals at 0.562 subject to Rule 16b-3 | ||
Paula Ragan over six months ago Disposition of 6724 shares by Paula Ragan of X4 Pharmaceuticals at 2.23 subject to Rule 16b-3 |
X4 Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4655) % which means that it has lost $0.4655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2635) %, meaning that it created substantial loss on money invested by shareholders. X4 Pharmaceuticals' management efficiency ratios could be used to measure how well X4 Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/26/2025, Return On Tangible Assets is likely to drop to -0.74. In addition to that, Return On Capital Employed is likely to drop to -1.04. At this time, X4 Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 02/26/2025, Net Tangible Assets is likely to grow to about 68.5 M, while Non Current Assets Total are likely to drop slightly above 19.2 M.Similar Executives
| Found 8 records | CEO Age | ||
| Lars Joergensen | Novo Nordisk AS | 54 | |
| Lars Jorgensen | Novo Nordisk AS | 59 | |
| Scott Wolchko | Fate Therapeutics | 55 | |
| Gilmore MD | Editas Medicine | 61 | |
| Nessan Bermingham | Intellia Therapeutics | 52 | |
| Douglas Esq | Sarepta Therapeutics | 62 | |
| John MD | Intellia Therapeutics | 68 | |
| Gilmore ONeill | Editas Medicine | 60 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.47 |
X4 Pharmaceuticals Leadership Team
Elected by the shareholders, the X4 Pharmaceuticals' board of directors comprises two types of representatives: X4 Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XFOR. The board's role is to monitor X4 Pharmaceuticals' management team and ensure that shareholders' interests are well served. X4 Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, X4 Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Arbeit, Senior Research | ||
| Mary DiBiase, Chief Officer | ||
| Paula Ragan, President CEO, Secretary, Director | ||
| Keith MD, Founder Board | ||
| Pharm MPH, Vice Communications | ||
| Adam Mostafa, CFO, Treasurer, Assistant Secretary | ||
| Renato Skerlj, Founder | ||
| Arthur Taveras, Chief Officer | ||
| Murray MD, Interim Director | ||
| Mark MBA, Chief Officer | ||
| Richard MD, Chairman Founder | ||
| MBA MD, Chief Officer |
XFOR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is X4 Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (61.61) % | ||||
| Current Valuation | 20.04 M | ||||
| Shares Outstanding | 170.55 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 59.17 % | ||||
| Number Of Shares Shorted | 16.61 M | ||||
| Price To Book | 1.29 X | ||||
| Price To Sales | 66.24 X |
Pair Trading with X4 Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against XFOR Stock
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.